Insmed Incorporated (NASDAQ:INSM) Insider Sells $7,291,200.00 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 91,140 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $76.58 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market cap of $13.70 billion, a price-to-earnings ratio of -13.80 and a beta of 1.12. The business has a 50-day simple moving average of $72.40 and a two-hundred day simple moving average of $72.93. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.63.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter last year, the business posted ($1.10) EPS. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. On average, analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of research reports. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Bank of America raised their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upped their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently added to or reduced their stakes in INSM. V Square Quantitative Management LLC purchased a new stake in Insmed during the third quarter valued at $30,000. GAMMA Investing LLC increased its position in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Spire Wealth Management bought a new position in shares of Insmed in the 4th quarter worth approximately $47,000. Exchange Traded Concepts LLC boosted its holdings in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Insmed during the fourth quarter valued at approximately $86,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.